Revenue segments as reported by the company.

Product revenues, net

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development expenses

Acquired in-process research and development expenses

Selling, general and administrative expenses

Change in fair value of contingent consideration

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vertex Pharmaceuticals reports robust earnings, eyes growth in diverse therapies

Vertex Pharmaceuticals delivered strong financial results, provided optimistic revenue guidance for 2023, and emphasized investments in R&D and commercial capabilities. The company faces challenges with escalating costs and the need for clearer long-term financial goals. However, Vertex remains well-positioned to capitalize on growth opportunities in the healthcare market.

Vertex Pharmaceuticals reports robust Q1 growth and innovative pipeline

Vertex Pharmaceuticals had a strong Q1 2023 performance with revenue growth and ongoing investments in innovative therapies.
The company faces challenges in managing operating expenses and ensuring successful launches amidst competitive pressures.
However, Vertex's strengths lie in its diverse pipeline, regulatory approvals, and focus on transformative therapies.
Opportunities exist in addressing unmet medical needs, pursuing revenue growth in pain relief markets, and advancing non-opioid treatments.

Vertex Pharmaceuticals reports robust Q2 growth and pipeline advancements

Vertex Pharmaceuticals showed strong revenue growth and pipeline progress.
Challenges include slower uptake for gene therapies and market access.
Opportunities lie in reimbursement models, new therapy launches, and program advancements.
Overall, Vertex is strategically positioned for growth and innovation.

Vertex Pharmaceuticals reports strong Q3 growth and pipeline optimism

Vertex Pharmaceuticals shows solid financial performance and a robust pipeline of innovative therapies.
Challenges include navigating patient complexities, regulatory reviews, and market differentiation.
Opportunities lie in market expansion, therapeutic advancements, and strategic growth initiatives.
Overall, Vertex's focus on autonomy, innovation, and financial strength positions it for future success.

Vertex Pharmaceuticals reports robust Q4 earnings and strategic advancements

Vertex Pharmaceuticals delivered a strong performance in Q4 2023, driven by revenue growth, positive trial outcomes, and strategic advancements in its pipeline.
The company's focus on commercial diversification, regulatory approvals, and upcoming milestones in 2024 position Vertex well for continued success and growth.
While facing challenges related to patient targeting, physician capacity, and market differentiation, Vertex has opportunities to innovate, expand its reach, and enhance market positioning.
Overall, Vertex Pharmaceuticals' 2023 achievements, financial strength, and strategic initiatives underscore a promising outlook for the company's future growth and success.

Vertex Pharmaceuticals reports strong Q1 earnings and pipeline advancements

Vertex Pharmaceuticals demonstrated robust financial performance and strategic advancements in its pipeline and acquisitions, positioning itself for continued growth.
While facing challenges in commercialization and policy landscape, Vertex's strong financial position and innovative capabilities provide a solid foundation for future success.
With a focus on rare diseases, pain management, and revenue diversification, Vertex is poised to capitalize on market opportunities and drive innovation in healthcare.

Vertex Pharmaceuticals delivered strong revenue growth driven by key product demand, while facing increased operating expenses.
The company is focused on expanding its pipeline and accelerating new therapy launches amidst regulatory and commercial challenges.
Anticipation is high for upcoming launches like vanzacaftor and suzetrigine, signaling potential growth opportunities for Vertex.

Vertex Pharmaceuticals excels in Q3, poised for innovative growth

Vertex Pharmaceuticals demonstrated robust financial performance, highlighted by revenue growth and promising early launches. The company's strong R&D pipeline and strategic focus on commercialization underscore its commitment to driving innovation and growth. Addressing analyst inquiries and seizing growth opportunities will be key for Vertex's continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis (CF) ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “In addition to data from clinical trials, long-term.

European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Mastercard

Transmedics Group Inc

Mastercard boasts a strong moat, rock-solid financials, and long-term trends that work in its favor. TransMedics Group is steadily disrupting the multibillion-dollar organ transplant market.

Prediction: 3 Stocks That Could Trounce the Market

Amgen

ARK Innovation ETF

Global X Health & Wellness Thematic ETF

iShares U.S. Pharmaceuticals ETF

Eli Lilly

A new ETF hit the market Tuesday, creating buzz for its exposure to popular weight-loss drugs, while expanding the roster of thematic ETFs available for investors willing to pay up for stock-picking prowess.

New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade

Applied Optoelectronics

CRISPR Therapeutics

Golden Heaven Group Holdings Ltd

The November rally continues with more names joining in. These five stock have outperformed with gains as high as 85% in November.

These Stocks Are Exploding In The November Stock Market Rally

Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.

Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). CASGEVY has been authorized.

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

ChargePoint Holdings

Medtronic

Rocket Lab USA

SharkNinja Inc

Tilray Brands

One of my favorite investment strategies when seeking forever stocks is to look to past trends that turned stale. Think of some of the hottest sectors in the past five years that saw massive investor interest before falling back to Earth.

Invest in the Future With These 7 Forever Stocks

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Jefferies Global Healthcare Conference Call November 14, 2023 3:30 AM ET Company Participants Stuart Arbuckle - Executive Vice President and Chief Operating Officer Conference Call Participants Michael Yee - Jefferies Michael Yee All right. Good morning, everybody.

Vertex Pharmaceuticals Incorporated (VRTX) Jefferies Global Healthcare Conference Call Transcript

Beam Therapeutics

Twilio

Twilio could be poised to use AI to disrupt customer communications. Beam Therapeutics is a pioneer in developing therapies using a highly precise method of gene editing.

Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer David Altshuler - Chief Scientific Officer Conference Call Participants Colin Bristow - UBS Colin Bristow Good afternoon, and welcome to the UBS Biopharma Conference. I'm Colin Bristow, one of the biotech analysts here.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Biopharma Conference (Transcript)

AbbVie

Axsome Therapeutics

AbbVie looks like a bargain that has stronger growth on the way. Axsome Therapeutics is in the early innings of what could be an exciting growth story.

3 Growth Stocks to Buy Right Now Without Any Hesitation

CrowdStrike

Lovesac Company

Visa

The Nasdaq Composite has swung like a pendulum between bull and bear markets since the start of 2020. A 15% decline in the index over the past two years might sound disappointing, but it's actually a blessing in disguise for long-term investors.

4 First-in-Their-Class Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment, and that business generates billions of dollars in annual revenue. The biotech has treatment candidate in another indication that's close to the regulatory finish line.

This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues

Shares of Vertex Pharmaceuticals, Inc. NASDAQ: VRTX are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a slight miss on the top line.

Why you can make Vertex Pharmaceuticals a buy on any pullback

The headline numbers for Vertex (VRTX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Vertex's Q3 update could have made some investors at least a little more nervous. However, there are four reasons some might be concerned that are easily debunked.

4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked

Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.

Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q3 2023 Earnings Call Transcript November 6, 2023 4:30 PM ET Company Participants Susie Lisa - CFA, Senior Vice President of Investor Relations Reshma Kewalramani - President & Chief Executive Officer Stuart Arbuckle - Executive Vice President & Chief Operating Officer Charlie Wagner - Executive Vice President & Chief Financial Officer Conference Call Participants Geoff Meacham - Bank of America Robyn Karnauskas - Truist Securities Salveen Richter - Goldman Sachs Phil Nadeau - TD Cowen Mohit Bansal - Wells Fargo Jessica Fye - JPMorgan David Risinger - Leerink Partners Evan Seigerman - BMO Capital Markets Liisa Bayko - Evercore ISI Michael Yee - Jefferies Terence Flynn - Morgan Stanley Operator Good day and welcome to the Vertex Pharmaceuticals Third Quarter 2023 Conference Call. All participants will be in a listen only mode.

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2023 Earnings Call Transcript

Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.08 per share, beating the Zacks Consensus Estimate of $3.92 per share. This compares to earnings of $4.01 per share a year ago.

Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings Estimates

Vertex Pharmaceuticals missed Wall Street estimates for third-quarter sales on Monday, hurt by weaker-than-expected demand for its older cystic fibrosis (CF) treatments.

Vertex Pharma misses sales estimates on weak demand for older CF treatments

Late Monday, Vertex reported adjusted earnings of $4.08 per share on $2.48 billion in third-quarter sales. In response, VRTX stock slipped.

IBD Tech Leader Vertex Boosts Outlook After Strong Earnings

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2023, raised full year 2023 guidance for product revenue and reiterated full year 2023 guidance for operating expenses. “Vertex has delivered another strong quarter across the business. We remain relentless in our commitment to reach more patients with our cystic fibrosis medicines, while preparing for the potential launch of exa-cel.

Vertex Reports Third Quarter 2023 Financial Results

Young English sufferers of cystic fibrosis (CF) face new uncertainty after regulators published proposals which, if enacted, would restrict access to potentially life-changing treatments on cost grounds.

England's young cystic fibrosis patients face new treatment worry

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is It Worth Investing in Vertex (VRTX) Based on Wall Street's Bullish Views?

Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel.

News for Vertex Pharmaceuticals Stock (VRTX)